CTOR CITIUS ONCOLOGY, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1851484 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-73.3%
TTM EPS YoY-26.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-126.6%
ROA-45.2%
ROIC (approx.)-132.9%
Asset turnover—
Leverage & solvency
Liabilities / assets64.0%
Debt / equity0.00x
Current ratio0.73x
Interest coverage-128.56x
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.49M | $1.67M | $3.94M | — | — | — | — | — |
| Cost of revenue | $491,843 | $328,878 | $789,208 | — | — | — | — | — |
| Gross profit | $1.00M | $1.34M | $3.15M | — | — | — | — | — |
| R&D expense | $218,496 | $1.08M | $1.02M | $1.08M | $938,277 | $3.14M | $1.26M | $1.30M |
| SG&A expense | $4.22M | $23.63M | $2.86M | $1.34M | $1.88M | $2.24M | $3.32M | $3.71M |
| Operating income | -$8.72M | -$28.61M | -$5.25M | -$4.71M | -$4.94M | -$7.47M | -$6.39M | -$6.67M |
| Interest expense | $231,732 | $33,031 | $45,841 | $57,277 | $160,755 | — | — | — |
| Pretax income | -$9.03M | -$26.84M | -$5.27M | -$4.73M | -$5.11M | -$7.47M | -$6.39M | -$6.67M |
| Income tax | -$107,347 | -$231,210 | $264,240 | $264,240 | $264,240 | $264,240 | $264,240 | $144,000 |
| Net income | -$8.92M | -$26.61M | -$5.53M | -$5.00M | -$5.37M | -$7.74M | -$6.66M | -$6.81M |
| EPS (basic) | -0.08 | -0.27 | -0.06 | — | -0.08 | -0.11 | -0.09 | — |
| EPS (diluted) | -0.08 | -0.27 | -0.06 | — | -0.08 | -0.11 | -0.09 | — |
| Weighted avg. shares (diluted) | 107.89M | 100.03M | 87.46M | — | 71.55M | 71.55M | 71.55M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $16.56M | $2.63M | $7.30M | $3.92M | $112 | $112 | $112 | $112 |
| Receivables | $686,235 | $1.08M | $4.05M | — | — | — | — | — |
| Inventory | $22.63M | $22.66M | $22.64M | $22.29M | $17.21M | $15.34M | $14.38M | $8.27M |
| Current assets | $42.71M | $29.42M | $37.15M | $27.54M | $18.31M | $18.04M | $17.08M | $10.97M |
| Total assets | $112.09M | $100.70M | $109.97M | $100.94M | $91.71M | $91.44M | $90.48M | $84.37M |
| Current liabilities | $58.79M | $58.81M | $44.71M | $49.49M | $52.99M | $49.74M | $43.40M | $32.70M |
| Total liabilities | $71.71M | $65.43M | $51.56M | $56.08M | $59.31M | $55.80M | $49.19M | $38.23M |
| Shareholders' equity | $40.38M | $35.27M | $58.41M | $44.87M | $32.40M | $35.64M | $41.29M | $46.14M |
| Shares outstanding | 105.76M | 92.98M | 84.80M | 83.51M | 71.55M | 71.55M | 71.55M | 71.55M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.71M | -$3.83M | -$7.35M | — | — | — | — | $902,926 |
| Investing cash flow | -$2.00M | -$600,000 | -$4.40M | — | — | — | — | -$29.15M |
| Financing cash flow | $18.64M | -$231,199 | $15.13M | — | — | — | — | $28.27M |
| Stock-based compensation | $3.56M | $3.53M | $3.96M | $2.30M | $2.13M | $2.09M | $1.81M | $1.67M |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.